Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids

Eugenia Mata-Greenwood, John M. Stewart, Robin H Steinhorn, William J. Pearce

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE - : Chronic therapy with synthetic glucocorticoids has been associated with cardiovascular side effects, although differential interindividual susceptibility to glucocorticoids has been observed. The objective of this study was to identify the molecular mechanisms leading to differential glucocorticoid responses in endothelial cells. APPROACH AND RESULTS - : We tested the sensitivity of 42 human umbilical vein endothelial cells (HUVECs) to dexamethasone as determined by changes in gene expression, promoter transactivation, and procoagulant activity. We identified that 16 HUVECs were sensitive in every test, 14 HUVECs were sensitive in at least 1 test and 12 HUVECs were resistant in every test to dexamethasone. Nuclear translocation assays revealed that Dex-sensitive HUVECs have higher basal and Dex-stimulated levels of nuclear glucocorticoid receptor compared with Dex-resistant HUVECs. Cycloheximide assays revealed that Dex-resistant HUVECs have significantly shorter glucocorticoid receptor protein half-lives than Dex-sensitive HUVECs. Dex-resistant HUVECs have a stronger interaction of glucocorticoid receptor with the proteasomal recruiting protein, BCL2-associated athanogene 1 (BAG1), as shown by immunoprecipitation assays. Silencing BAG1 expression increased Dex-sensitivity in resistant HUVECs, whereas BAG1 overexpression decreased Dex-sensitivity in sensitive HUVECs. Finally, Dex-resistant HUVECs presented higher BAG1 expression than Dex-sensitive HUVECs. CONCLUSIONS - : In vitro endothelial sensitivity to Dex varies within individuals and is inversely proportional to BAG1 protein expression and glucocorticoid receptor protein turnover.

Original languageEnglish (US)
Pages (from-to)1046-1055
Number of pages10
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume33
Issue number5
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Human Umbilical Vein Endothelial Cells
Glucocorticoids
Endothelial Cells
Glucocorticoid Receptors
Dexamethasone
Cycloheximide
Cytoplasmic and Nuclear Receptors
Immunoprecipitation
Transcriptional Activation
Proteins

Keywords

  • coagulation
  • endothelium
  • glucocorticoids
  • sensitivity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids. / Mata-Greenwood, Eugenia; Stewart, John M.; Steinhorn, Robin H; Pearce, William J.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, No. 5, 05.2013, p. 1046-1055.

Research output: Contribution to journalArticle

Mata-Greenwood, Eugenia ; Stewart, John M. ; Steinhorn, Robin H ; Pearce, William J. / Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2013 ; Vol. 33, No. 5. pp. 1046-1055.
@article{26f3ff167cb4479792aa487a7f3bb18c,
title = "Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids",
abstract = "OBJECTIVE - : Chronic therapy with synthetic glucocorticoids has been associated with cardiovascular side effects, although differential interindividual susceptibility to glucocorticoids has been observed. The objective of this study was to identify the molecular mechanisms leading to differential glucocorticoid responses in endothelial cells. APPROACH AND RESULTS - : We tested the sensitivity of 42 human umbilical vein endothelial cells (HUVECs) to dexamethasone as determined by changes in gene expression, promoter transactivation, and procoagulant activity. We identified that 16 HUVECs were sensitive in every test, 14 HUVECs were sensitive in at least 1 test and 12 HUVECs were resistant in every test to dexamethasone. Nuclear translocation assays revealed that Dex-sensitive HUVECs have higher basal and Dex-stimulated levels of nuclear glucocorticoid receptor compared with Dex-resistant HUVECs. Cycloheximide assays revealed that Dex-resistant HUVECs have significantly shorter glucocorticoid receptor protein half-lives than Dex-sensitive HUVECs. Dex-resistant HUVECs have a stronger interaction of glucocorticoid receptor with the proteasomal recruiting protein, BCL2-associated athanogene 1 (BAG1), as shown by immunoprecipitation assays. Silencing BAG1 expression increased Dex-sensitivity in resistant HUVECs, whereas BAG1 overexpression decreased Dex-sensitivity in sensitive HUVECs. Finally, Dex-resistant HUVECs presented higher BAG1 expression than Dex-sensitive HUVECs. CONCLUSIONS - : In vitro endothelial sensitivity to Dex varies within individuals and is inversely proportional to BAG1 protein expression and glucocorticoid receptor protein turnover.",
keywords = "coagulation, endothelium, glucocorticoids, sensitivity",
author = "Eugenia Mata-Greenwood and Stewart, {John M.} and Steinhorn, {Robin H} and Pearce, {William J.}",
year = "2013",
month = "5",
doi = "10.1161/ATVBAHA.113.301247",
language = "English (US)",
volume = "33",
pages = "1046--1055",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids

AU - Mata-Greenwood, Eugenia

AU - Stewart, John M.

AU - Steinhorn, Robin H

AU - Pearce, William J.

PY - 2013/5

Y1 - 2013/5

N2 - OBJECTIVE - : Chronic therapy with synthetic glucocorticoids has been associated with cardiovascular side effects, although differential interindividual susceptibility to glucocorticoids has been observed. The objective of this study was to identify the molecular mechanisms leading to differential glucocorticoid responses in endothelial cells. APPROACH AND RESULTS - : We tested the sensitivity of 42 human umbilical vein endothelial cells (HUVECs) to dexamethasone as determined by changes in gene expression, promoter transactivation, and procoagulant activity. We identified that 16 HUVECs were sensitive in every test, 14 HUVECs were sensitive in at least 1 test and 12 HUVECs were resistant in every test to dexamethasone. Nuclear translocation assays revealed that Dex-sensitive HUVECs have higher basal and Dex-stimulated levels of nuclear glucocorticoid receptor compared with Dex-resistant HUVECs. Cycloheximide assays revealed that Dex-resistant HUVECs have significantly shorter glucocorticoid receptor protein half-lives than Dex-sensitive HUVECs. Dex-resistant HUVECs have a stronger interaction of glucocorticoid receptor with the proteasomal recruiting protein, BCL2-associated athanogene 1 (BAG1), as shown by immunoprecipitation assays. Silencing BAG1 expression increased Dex-sensitivity in resistant HUVECs, whereas BAG1 overexpression decreased Dex-sensitivity in sensitive HUVECs. Finally, Dex-resistant HUVECs presented higher BAG1 expression than Dex-sensitive HUVECs. CONCLUSIONS - : In vitro endothelial sensitivity to Dex varies within individuals and is inversely proportional to BAG1 protein expression and glucocorticoid receptor protein turnover.

AB - OBJECTIVE - : Chronic therapy with synthetic glucocorticoids has been associated with cardiovascular side effects, although differential interindividual susceptibility to glucocorticoids has been observed. The objective of this study was to identify the molecular mechanisms leading to differential glucocorticoid responses in endothelial cells. APPROACH AND RESULTS - : We tested the sensitivity of 42 human umbilical vein endothelial cells (HUVECs) to dexamethasone as determined by changes in gene expression, promoter transactivation, and procoagulant activity. We identified that 16 HUVECs were sensitive in every test, 14 HUVECs were sensitive in at least 1 test and 12 HUVECs were resistant in every test to dexamethasone. Nuclear translocation assays revealed that Dex-sensitive HUVECs have higher basal and Dex-stimulated levels of nuclear glucocorticoid receptor compared with Dex-resistant HUVECs. Cycloheximide assays revealed that Dex-resistant HUVECs have significantly shorter glucocorticoid receptor protein half-lives than Dex-sensitive HUVECs. Dex-resistant HUVECs have a stronger interaction of glucocorticoid receptor with the proteasomal recruiting protein, BCL2-associated athanogene 1 (BAG1), as shown by immunoprecipitation assays. Silencing BAG1 expression increased Dex-sensitivity in resistant HUVECs, whereas BAG1 overexpression decreased Dex-sensitivity in sensitive HUVECs. Finally, Dex-resistant HUVECs presented higher BAG1 expression than Dex-sensitive HUVECs. CONCLUSIONS - : In vitro endothelial sensitivity to Dex varies within individuals and is inversely proportional to BAG1 protein expression and glucocorticoid receptor protein turnover.

KW - coagulation

KW - endothelium

KW - glucocorticoids

KW - sensitivity

UR - http://www.scopus.com/inward/record.url?scp=84876285422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876285422&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.113.301247

DO - 10.1161/ATVBAHA.113.301247

M3 - Article

C2 - 23493285

AN - SCOPUS:84876285422

VL - 33

SP - 1046

EP - 1055

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 5

ER -